<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1489">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371835</url>
  </required_header>
  <id_info>
    <org_study_id>2020-04-COHIVE</org_study_id>
    <nct_id>NCT04371835</nct_id>
  </id_info>
  <brief_title>COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings</brief_title>
  <official_title>COVID-19 in People Living With HIV: Evaluation of Risk Factors and Outcomes in Resource-limited Settings. A Pooled Substudy of ADVANCE, D²EFT, DolPHIN2 and NAMSAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Witwatersrand, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNITAID</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COHIVE is an observational cohort nested in four antiretroviral therapy research studies&#xD;
      (ADVANCE - NCT03122262; D²EFT - NCT03017872; DolPHIN2 - NCT03249181 and NAMSAL-ANRS12313 -&#xD;
      NCT02777229). COHIVE will include participants who are possible COVID-19 cases with symptoms&#xD;
      or confirmed COVID-19 cases, and participants who agree to have a serology testing for&#xD;
      SARS-CoV-2 regardless of COVID-19 history.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COHIVE is an observational cohort study nested within four parent open label randomised&#xD;
      clinical trials of first- and second-line antiretroviral therapies (ADVANCE - NCT03122262;&#xD;
      D²EFT - NCT03017872; DolPHIN2 - NCT03249181 and NAMSAL-ANRS12313 - NCT02777229). COHIVE&#xD;
      objective is to study the occurrence and outcomes of COVID-19 in people living with HIV&#xD;
      across a variety of clinical settings. Taken together, these pivotal trials provide an&#xD;
      established population and encompass a range of HIV therapies, HIV populations, and&#xD;
      geographic regions to capture the full spectrum of these global public health emergency as it&#xD;
      pertains to people living with HIV.&#xD;
&#xD;
      The sample will include participants who are possible symptomatic or confirmed COVID-19&#xD;
      cases, and participants who agree to enrol in the SARS-CoV-2 seroprevalence cohort&#xD;
      (regardless of SARS-CoV-2 infection). Approximately 2,500 participants are enrolled in these&#xD;
      4 studies.&#xD;
&#xD;
      Enrolment into COHIVE substudy is voluntary and optional for participants in ADVANCE, D²EFT,&#xD;
      DolPHIN2 and NAMSAL studies. Parameters relevant to COHIVE substudy including demographics,&#xD;
      arm of randomised ART, medical and HIV history, immunological and virological results,&#xD;
      adverse events at required time points will be collected as part of parent studies. Substudy&#xD;
      specific assessments performed at baseline include optional sample collection for SARS-CoV-2&#xD;
      RT-PCR and serology; for the possible symptomatic or confirmed COVID-19 cases, the management&#xD;
      of the patients, diagnostic test results, and outcomes, will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical features of symptomatic COVID-19 in people living with HIV (PLWH)</measure>
    <time_frame>At baseline</time_frame>
    <description>To characterise the clinical features of symptomatic COVID-19 in PLWH (cardio-respiratory and other clinical signs or symptoms), described overall and by HIV and comorbid disease factors including pregnancy status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical outcomes of symptomatic COVID-19 in PLWH</measure>
    <time_frame>At Day 28</time_frame>
    <description>To characterise the clinical outcomes of symptomatic COVID-19 in PLWH, assessing the outcomes of patients including the percentage of patients who are fully recovered, required hospitalisation, developed severe illness (ICU admission or equivalent) or died.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical outcomes of symptomatic COVID-19 in PLWH</measure>
    <time_frame>At Month 3</time_frame>
    <description>To characterise the clinical outcomes of symptomatic COVID-19 in PLWH, assessing the outcomes of patients including the percentage of patients who are fully recovered, required hospitalisation, developed severe illness (ICU admission or equivalent) or died.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprevalence of COVID-19 in all parent study participants</measure>
    <time_frame>Through study completion, an average of one year</time_frame>
    <description>To determine seroprevalence of COVID-19 in all parent study participants regardless of COVID-19 history.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>HIV-infection/Aids</condition>
  <condition>Coronavirus Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The substudy will be proposed to all the sites participating in ADVANCE, D²EFT, DolPHIN2&#xD;
        and NAMSAL studies. This substudy will enrol eligible patients with i) confirmed or&#xD;
        suspected infection with SARS-CoV-2 and ii) any participants of the 4 parent studies who&#xD;
        accept to enrol in the seroprevalence cohort during a scheduled parent study protocol visit&#xD;
        following control of the epidemic in country.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old.&#xD;
&#xD;
          -  Either: i) Meet local testing criteria for COVID-19, or present with symptoms that in&#xD;
             the opinion of the investigator are consistent with COVID-19 and do not have an&#xD;
             alternative explanation, or have tested elsewhere and found positive for COVID-19; OR&#xD;
             ii) Agree for serology testing for SARS-CoV2, regardless of history of COVID-19.&#xD;
&#xD;
          -  Have signed the informed consent of one of the parent study.&#xD;
&#xD;
          -  Give informed consent to the COHIVE substudy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refuse to participate in the COHIVE substudy.&#xD;
&#xD;
          -  Any condition which would place the participant at risk if they participated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Calmy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Delaporte, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRD, Inserm, University of Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saye Khoo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuelle Papot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Polizzotto, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francois WD Venter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wits Reproductive Health and HIV Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joana Woods, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wits Reproductive Health and HIV Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria E Arriaga, PhD</last_name>
    <phone>+61 2 9385 0900</phone>
    <phone_ext>50401</phone_ext>
    <email>cohive@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital G de Agudos JM Ramos Mejia</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad De Buenos Aires</state>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Losso</last_name>
      <phone>5411 4127 0276</phone>
      <email>mlosso@hivramos.org.ar</email>
    </contact>
    <investigator>
      <last_name>Marcelo Losso, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laboratório de Pesquisa Clinica Em Hiv/Aids - Instituto Nacional de Infectologia - Fiocruz</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Grinsztejn</last_name>
      <phone>+552122707064</phone>
      <email>beatriz.grinsztejn@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Gama</last_name>
      <phone>+552138659614</phone>
      <email>kelly.gama@ini.fiocruz.br</email>
    </contact_backup>
    <investigator>
      <last_name>Beatriz Grinsztejn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Yaoundé</name>
      <address>
        <city>Yaoundé</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Tovar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cité Verte Hospital</name>
      <address>
        <city>Yaoundé</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Tovar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Militaire de Région N°1</name>
      <address>
        <city>Yaoundé</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Tovar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CART CRS, VHS Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nagalingeswaran Kumarasamy</last_name>
      <phone>91 917 691 2007</phone>
      <email>kumarasamy@yrgcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Faith Beulah</last_name>
      <phone>91 44 39106811</phone>
      <email>beulah@yrgcare.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Univerity of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret CH Tan</last_name>
      <phone>+60379492622</phone>
      <email>margarettan455@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Iskandar S Raja Azwa, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Human Virology, Nigeria (IHVN)</name>
      <address>
        <city>Abuja</city>
        <zip>9396</zip>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nnakelu Eriobu</last_name>
      <phone>+2347039469273</phone>
      <email>neriobu@ihvnigeria.org</email>
    </contact>
    <contact_backup>
      <last_name>Maryam Almujtaba</last_name>
      <phone>+2347039469273</phone>
      <email>malmujtaba@ihvnigeria.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nnakelu Eriobu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Kaplan</last_name>
      <email>Richard.Kaplan@hiv-research.org.za</email>
    </contact>
    <investigator>
      <last_name>Richard Kaplan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit (PHRU)</name>
      <address>
        <city>Johannesburg</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lerato Mohapi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical HIV Research Unit (CHRU), Wits Health Consotium (Pty) Ltd</name>
      <address>
        <city>Johannesburg</city>
        <zip>2041</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaclyn Ann Bennet</last_name>
      <phone>27 11 276 8800</phone>
      <email>jbennet@witshealth.co.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ezintsha</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joana Woods</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIV-NAT (The HIV Netherlands Australia Thailand Research Collaboration), Thai Red Cross AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anchalee Avihingsanon</last_name>
      <phone>+662 652 3040</phone>
      <phone_ext>107</phone_ext>
      <email>anchaleea2009@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kanitta Pussadee</last_name>
      <phone>+662 652 3040</phone>
      <phone_ext>202</phone_ext>
      <email>kanitta.p@hivnat.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anchalee Avihingsanon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Kintu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe Clinical Research Centre</name>
      <address>
        <city>Harare</city>
        <zip>263</zip>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ennie Chidziva, MSc</last_name>
      <phone>+263772924389</phone>
      <email>echidziva@uzcrc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Cameroon</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Nigeria</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

